CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 116 enrolled
Drug / intervention
allogeneic hematopoietic stem cell transplantation +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01596257
NCT01596257Phase 2Completed
CompareCT.gov

Randomized Phase II Trial of Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation

Memorial Sloan Kettering Cancer Center·interventional·Posted May 10, 2012·Updated Dec 29, 2022

In Brief

A Phase 2 clinical trial evaluating allogeneic hematopoietic stem cell transplantation and CliniMACS for Leukemia. Completed, enrolled 116 participants across 1 site.

Detailed Summary

The purpose of this study is to find out if getting a blood stem cell transplant with donor stem cells given over several days is better than getting a blood stem cell transplant with donor stem cells given over 1 day. We want to find out which procedure over will result in improved recovery of blood and immune function after transplant. When donor stem cells are given over various days in mice, the blood and immune system recovery is quicker.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 10, 2012
Enrollment StartMay 5, 2012
Primary CompletionAug 30, 2021
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 14.1 years ago

Interventions

allogeneic hematopoietic stem cell transplantationprocedure

Undergo allogeneic hematopoietic stem cell transplant

CliniMACSdevice